Statins with Less Hepatic Metabolism

Metabolism and Pharmacokinetics

Hydrophilic statins such as pravastatin and rosuvastatin are preferred when less hepatic metabolism is desired, as they are not significantly metabolized by the cytochrome P450 enzyme system 1
Pravastatin is minimally metabolized and not significantly eliminated via CYP450 enzymes, with 20% renal excretion of unchanged drug 2
Fluvastatin is metabolized by CYP2C9 with only 5% renal excretion 2
Pitavastatin undergoes minimal CYP2C9 metabolism with 15% renal excretion 2
Atorvastatin, lovastatin, and simvastatin undergo significant CYP3A4 metabolism, making them more susceptible to drug interactions 1, 2

Hydrophilic statins are preferred when used with medications that inhibit CYP450-3A4, such as cyclosporine and certain antibiotics 3, 4
In liver transplant recipients, hydrophilic statins (fluvastatin and pravastatin) are preferred as they are not metabolized by cytochrome P450-3A4 and cause fewer metabolic interactions 3, 4
Atorvastatin has the least renal excretion (<2%), making it potentially safer in severe renal impairment 2

All statins have been associated with muscle-related toxicity, but the risk varies based on their pharmacokinetic properties 5
The risk of myopathy increases with concomitant use of medications that inhibit statin metabolism 5
When statins are combined with fibrates, pravastatin may have a lower risk of myopathy compared to statins metabolized by CYP3A4 6, 7
Be cautious with gemfibrozil combinations with any statin, as this significantly increases myopathy risk 8, 9
Remember that even statins with less hepatic metabolism can still have drug interactions through other mechanisms like transporter proteins 1, 6

Pravastatin is minimally metabolized and not significantly eliminated via CYP450 enzymes, with only 20% renal excretion of unchanged drug, according to the American Heart Association 10
The combination of statins with gemfibrozil significantly increases the risk of rhabdomyolysis, which can lead to acute kidney injury, as reported by the American College of Cardiology 10, 11
Macrolide antibiotics combined with statins metabolized by CYP3A4 increase hospitalizations for AKI from rhabdomyolysis, though this is less relevant for pravastatin given its minimal CYP450 metabolism, as noted by the National Kidney Foundation 12
General nephrotoxin avoidance principles apply to all patients with kidney disease, but pravastatin is not among the agents to avoid, according to the National Kidney Foundation 13

Avoid combining pravastatin (or any statin) with gemfibrozil due to increased myopathy risk; if fibrate combination is necessary, fenofibrate is preferred, as recommended by the American College of Cardiology 10, 11